Allon’s built a strong safety foundation in large conventional Phase 1 studies and then identify multiple opportunities to show human efficacy in Phase 2 studies. Based on a strong foundation of Phase 1 safety studies and multiple Phase 2 efficacy studies, Allon’s clinical development strategy is to pursue first approval in an orphan movement disorder and dementia market called progressive supranuclear palsy.
Here is the Company’s pipeline of products:
Allon is currently conducting a Phase 2/3 clinical trial in progressive supranuclear palsy (PSP), a type of frontotemporal dementia (FTD). Often mis-diagnosed as Parkinson’s disease or Alzheimer’s disease, FTDs are a group of rapidly progressive and fatal degenerative brain diseases. In addition, about 50 percent of these disorders are tau-related diseases, or tauopathies.
Allon’s technology is recognized as the most clinically advanced tau-related therapy in development.